What You Haven't Heard Of Nutlin-3 Will Amaze You

[2,3,4,5] Footnotes Source of Support: Nil. Conflict of Interest: None declared.""The combination of rituximab with cyclophosphamide, doxorubicin, vincristine, and ABT-737 clinical trial prednisone (R-CHOP) has produced significant survival benefits, especially in elderly patients with untreated diffuse large B-cell lymphoma (DLBCL), compared to the CHOP regimen [1]. Although the immunochemotherapy improved clinical outcomes, some patients experience early refractoriness, unsatisfactory response, or relapse. High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) has become the standard of care for younger patients with chemosensitive relapsed non-Hodgkin lymphoma (NHL) and patients with primary refractory aggressive NHL [2]. In a recent study, the second-line age-adjusted International Prognostic Index (aa-IPI) accurately Thymidine kinase reflected prognosis in a group of patients with relapsed NHL [3]. The intergroup Collaborative Trial in Relapsed Aggressive Lymphoma evaluated salvage therapy regimens in HDT/ASCT-eligible patients, and the study identified several prognostic factors, including prior exposure to rituximab, early relapse (Nutlin-3 clinical trial Hwasun Hospital, Seoul National University Bundang Hospital, Gachon University Gil Medical Center, and Pusan National University Yangsan Hospital). Patients who experienced relapse following R-CHOP therapy for DLBCL between 2006 and 2012 were included. Patients were excluded from the study if they had received additional therapies such as rituximab maintenance therapy after R-CHOP or underwent ASCT. During the period, all patients received treatment with the ifosfamide, carboplatin, and etoposide (ICE) regimen. The patients who received radiotherapy, and other types of salvage chemotherapy were excluded. This study was approved by the local Institutional Review Board. Salvage therapy schedule The ICE regimen was also administered in an inpatient setting.